# A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

> **NCT05155709** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** siremadlin
- **DRUG:** venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT05155709
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-17
- **Primary completion:** 2024-04-17
- **Final completion:** 2024-04-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155709, "A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT05155709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*